Should we treat genetic syndromes?

Ronald (Ron) Rosenfeld, C. K. Buckway

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

With the greater availability of GH due to the development of recombinant human GH, GH therapy has expanded well beyond the original FDA indication for GHD. We examine the NCGS database, comparing data for FDA-approved indications with data for 'other' conditions to see whether such expanded use is warranted. Although statistical analyses are of questionable validity because of the small size of some subpopulations and other factors discussed herein, certain trends emerge from the data captured by NCGS. We conclude that many clinical syndromes characterized by short stature are responsive to GH, at least in the short term. For many such syndromes, responsiveness is of the same magnitude as that seen in Turner's syndrome and, occasionally, GHD. If responsiveness to GH is the most important criterion for GH therapy, these 'other' conditions warrant an open-minded, prospective evaluation.

Original languageEnglish (US)
Pages (from-to)971-981
Number of pages11
JournalJournal of Pediatric Endocrinology and Metabolism
Volume13
Issue numberSUPPL. 2
StatePublished - 2000

Fingerprint

Turner Syndrome
Human Development
Databases
Therapeutics
SHORT syndrome

Keywords

  • Genetic syndromes
  • Growth hormone
  • Short stature

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Rosenfeld, R. R., & Buckway, C. K. (2000). Should we treat genetic syndromes? Journal of Pediatric Endocrinology and Metabolism, 13(SUPPL. 2), 971-981.

Should we treat genetic syndromes? / Rosenfeld, Ronald (Ron); Buckway, C. K.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 13, No. SUPPL. 2, 2000, p. 971-981.

Research output: Contribution to journalArticle

Rosenfeld, RR & Buckway, CK 2000, 'Should we treat genetic syndromes?', Journal of Pediatric Endocrinology and Metabolism, vol. 13, no. SUPPL. 2, pp. 971-981.
Rosenfeld, Ronald (Ron) ; Buckway, C. K. / Should we treat genetic syndromes?. In: Journal of Pediatric Endocrinology and Metabolism. 2000 ; Vol. 13, No. SUPPL. 2. pp. 971-981.
@article{44a3fb432db84f25b015f483abb70ade,
title = "Should we treat genetic syndromes?",
abstract = "With the greater availability of GH due to the development of recombinant human GH, GH therapy has expanded well beyond the original FDA indication for GHD. We examine the NCGS database, comparing data for FDA-approved indications with data for 'other' conditions to see whether such expanded use is warranted. Although statistical analyses are of questionable validity because of the small size of some subpopulations and other factors discussed herein, certain trends emerge from the data captured by NCGS. We conclude that many clinical syndromes characterized by short stature are responsive to GH, at least in the short term. For many such syndromes, responsiveness is of the same magnitude as that seen in Turner's syndrome and, occasionally, GHD. If responsiveness to GH is the most important criterion for GH therapy, these 'other' conditions warrant an open-minded, prospective evaluation.",
keywords = "Genetic syndromes, Growth hormone, Short stature",
author = "Rosenfeld, {Ronald (Ron)} and Buckway, {C. K.}",
year = "2000",
language = "English (US)",
volume = "13",
pages = "971--981",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Should we treat genetic syndromes?

AU - Rosenfeld, Ronald (Ron)

AU - Buckway, C. K.

PY - 2000

Y1 - 2000

N2 - With the greater availability of GH due to the development of recombinant human GH, GH therapy has expanded well beyond the original FDA indication for GHD. We examine the NCGS database, comparing data for FDA-approved indications with data for 'other' conditions to see whether such expanded use is warranted. Although statistical analyses are of questionable validity because of the small size of some subpopulations and other factors discussed herein, certain trends emerge from the data captured by NCGS. We conclude that many clinical syndromes characterized by short stature are responsive to GH, at least in the short term. For many such syndromes, responsiveness is of the same magnitude as that seen in Turner's syndrome and, occasionally, GHD. If responsiveness to GH is the most important criterion for GH therapy, these 'other' conditions warrant an open-minded, prospective evaluation.

AB - With the greater availability of GH due to the development of recombinant human GH, GH therapy has expanded well beyond the original FDA indication for GHD. We examine the NCGS database, comparing data for FDA-approved indications with data for 'other' conditions to see whether such expanded use is warranted. Although statistical analyses are of questionable validity because of the small size of some subpopulations and other factors discussed herein, certain trends emerge from the data captured by NCGS. We conclude that many clinical syndromes characterized by short stature are responsive to GH, at least in the short term. For many such syndromes, responsiveness is of the same magnitude as that seen in Turner's syndrome and, occasionally, GHD. If responsiveness to GH is the most important criterion for GH therapy, these 'other' conditions warrant an open-minded, prospective evaluation.

KW - Genetic syndromes

KW - Growth hormone

KW - Short stature

UR - http://www.scopus.com/inward/record.url?scp=0033792419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033792419&partnerID=8YFLogxK

M3 - Article

C2 - 11086650

AN - SCOPUS:0033792419

VL - 13

SP - 971

EP - 981

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - SUPPL. 2

ER -